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Foreword
Public health surveillance is the bedrock 
of outbreak and epidemic response, but it 
reaches far beyond infectious diseases. It is 
sometimes called the radar of public health: 
it allows health ofﬁ cials to map disease, spot 
patterns, identify causes, and target interven-
tions. Surveillance, for example, is central to 
understanding the increasing global burden 
of noncommunicable conditions. By helping 
to determine patterns and causes of morbidity 
and mortality, it can help guarantee access to 
safe food, clean water, pure air, and healthy 
environments. 
Surveillance, when conducted ethically, is the 
foundation for programs to promote human 
well-being at the population level. It can con-
tribute to reducing inequalities: pockets of suf-
fering that are unfair, unjust and preventable 
cannot be addressed if they are not ﬁ rst made 
visible. But surveillance is not without risks 
for participants and sometimes poses ethical 
dilemmas. Issues about privacy, autonomy, 
equity, and the common good need to be con-
sidered and balanced, and knowing how to do 
so can be challenging in practice. 
I am pleased to see WHO leading in this impor-
tant area by placing ethics at the heart of pub-
lic health surveillance. The WHO Guidelines on 
Ethical Issues in Public Health Surveillance is 
the ﬁ rst international framework of its kind, it 
ﬁ lls an important gap. The goal of the guide-
line development project was to  to help policy-
makers and practitioners navigate the ethical 
issues presented by public health surveillance. 
This document outlines 17 ethical guidelines 
that can assist everyone involved in public 
health surveillance, including ofﬁ cials in gov-
ernment agencies, health workers, NGOs and 
the private sector. I gratefully acknowledge 
the many experts and WHO colleagues who 
have made important contributions to this 
publication.
WHO has rightly asserted that public health 
surveillance, conducted in a manner that 
anticipates ethical challenges and proactively 
seeks to reduce unnecessary risks, provides the 
architecture for social well-being. It is now up 
to the global community and countries to take 
up this challenge and implement the guide-
lines in their surveillance systems.
Dr Marie-Paule Kieny 
Assistant Director-General
Health Systems and 
Innovation
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10 Introduction
I. Introduction
Disease surveillance has been a basic public 
health activity since the late nineteenth century 
(see Table 1). It is the foundation for initiatives 
to promote human well-being at the popula-
tion level. Public health surveillance is the bed-
rock of outbreak and epidemic response, but 
it reaches far beyond infectious diseases. It can 
contribute to reducing inequalities: pockets of 
suffering that are unfair, unjust, and prevent-
able cannot be addressed if they are not ﬁ rst 
made visible (1). It is central to understanding 
the increasing global burden of noncommuni-
cable conditions. By helping to determine pat-
terns and causes of morbidity and mortality, 
public health surveillance can help  guarantee 
access to safe food, clean water, pure air, 
and healthy environments. Continuous envi-
ronmental surveillance may not only identify 
concerns but also trigger alerts. Occupational 
disease surveillance can identify workplace 
exposures and lead to regulation. Surveillance 
can help create accountable institutions by 
providing information about health and its 
determinants. It can provide an evidentiary 
basis for establishing and evaluating public 
health policy. Surveillance, for example, will 
be central to the achievement of the United 
Nation’s Sustainable Development Goals. 
The availability of the results of surveillance 
enables and promotes policy choice. Thus, 
access to surveillance information can serve 
as a tool for advocacy when the results are 
Table 1. Dimensions of public health surveillance
Scope
Communicable 
diseases
Noncommunicable 
diseases
Environmental 
factors
Risk factors and 
risk markers
Health system Demographic 
variables
Health-related 
events (e.g. food 
and drug safety, 
vaccine reactions) 
↓
Objectives
Early detecting 
and warning 
of epidemics
Trend and 
spatial analyses
Risk detection Generating 
hypotheses
Monitoring of 
health system 
performance
Evaluation of 
control 
measures
Policy analysis
↓
Data collection tools
Registries Case reports Repeated 
surveys
Bio-banks Secondary 
data sources
Population-based 
(universal or 
sentinel sites)
Social media
↓
Types of analysis
Estimation of 
incidence or 
prevalence
Measurement of 
associations
Assessment 
of trends
Assessment of 
spatial patterns
Data mining
↓
Uses
Policy change Structural 
intervention
Case or epidemic 
detection
Testing of 
hypotheses
Implementation 
research
Quality 
assurance
Source: A.A. Haghdoost
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shared with populations and policy-makers in 
a timely, appropriate manner.
Yet surveillance has been the subject of some-
times bitter controversy. Public health sur-
veillance may limit not only privacy but also 
other civil liberties. For example, surveillance 
may trigger mandatory quarantine, isolation, 
or seizure of property during an epidemic 
(2). When surveillance involves name-based 
reporting (that is, reporting by name), it can, to 
the extent that populations are made aware, 
trigger profound concern about intrusions on 
privacy, discrimination, and stigmatization. 
Name-based reporting can also seriously harm 
people and property, as is seen when mob 
reactions supersede care, compassion and the 
effective rule of law. Concern is compounded 
in the absence of trust that the public health 
system will keep names secure or will release 
aggregated data and related information 
(referred to simply as “data” from this point 
forward, as records contain information that 
varies in type and scope) in a sensitive manner 
(2). In some countries, the HIV/AIDS pandemic 
sparked controversy about tracking by name 
those carrying the virus, but, even when con-
ﬁ dentiality was assured, when details of risky 
behaviour and affected populations became 
public, groups like gay sex workers and inject-
ing drug users experienced social harm such 
as discrimination and stigmatization. Because 
of these concerns, the HIV/AIDS epidemic 
spurred ethical and regulatory guidelines at 
both national and international levels that 
could be used in planning, collecting and then 
using personal and aggregated data. 
Just as often, however, failure to conduct public 
health surveillance has generated political and 
ethical controversy because of concern that 
“what doesn’t get counted doesn’t count”. 
Environmental and occupational health 
 advocates, for example, have long made this 
argument. Even for events deemed  critically 
important, yawning gaps in surveillance 
remain. The 2014–2016 Ebola virus disease 
crisis dramatically underscored the potentially 
devastating consequences of a lack of capacity 
to monitor the incidence and spread of disease. 
An effective public health or clinical response 
can be seriously hampered by the absence of 
such data. But if Ebola virus disease is a high-
proﬁ le example of the costs of inadequate 
systems and the importance of support from 
the global community for vital surveillance, 
many other occupational and environmental 
exposures – like asthma, silicosis and condi-
tions related to exposure to arsenic or lead – 
go uncounted in both high- and low-income 
countries. Some commentators have argued 
that, too often, only when a public health crisis 
becomes a “threat to international peace and 
security” does surveillance become a priority 
for wealthy countries (3). But even when sur-
veillance is a priority, fragmented, unlinked or 
consolidated data sets remain a problem for 
their effective use for public health purposes. 
While surveillance is often conducted without 
public knowledge or concern when the risk 
for stigma, discrimination or perpetuation of 
inequity is high, surveillance inevitably involves 
 conﬂ icts of values and judgements about how 
to advance public health goals without harm-
ing individuals or groups in society. Thus, the 
priorities and the distribution of resources 
for surveillance merit public debate, not only 
within societies but among global communi-
ties. Despite landmark international guidelines 
on the ethics of research, including epidemio-
logical  studies, and speciﬁ c ethical guidelines 
for surveillance of particular diseases and/
or in particular countries, there has been no 
international ethics framework to guide pub-
lic health surveillance systems in general that 
spans infectious  diseases, noncommunicable 
diseases (NCDs), disease outbreaks, environ-
mental and  occupational exposures, and even 
national borders. The Council for International 
P214263_WHO Guidelines on Ethical Issues.indd   11 20/06/17   2:42 PM
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Organizations of Medical Sciences (CIOMS), 
the World Medical Association and others 
have identiﬁ ed this gap (4). It is crucial to have 
ethical guidance as a baseline for judging 
public health surveillance for all diseases and 
exposure across national borders. 
The fragmented, disease-speciﬁ c nature of 
international guidance is not surprising, given 
the uneven, incomplete state of public health 
surveillance in both high- and low-resource 
settings and different national and subnational 
mandates for surveillance in different legal sys-
tems. It is imperative to address the ethics of 
public health surveillance in a way that cuts 
across conventional boundaries, for a number 
of reasons. 
Public health operates in an era of global 
health threats, such as AIDS, severe acute 
respiratory syndrome (SARS), inﬂ uenza, Ebola 
virus disease, Zika virus infection, obesity and 
coronary heart disease. Given the zoonotic ori-
gin of many of the conditions, surveillance will 
increasingly involve monitoring the animal–
human interface. For example, surveillance of 
food and animal feed for pathogens must be 
linked to surveillance for the same pathogens 
in humans. 
Surveillance is conducted in a context in which 
there have been signiﬁ cant advances in the 
capacity to collect and share data from previ-
ously unimagined sources, such as social media 
or geospatial mobile phone data. There have 
been parallel technological leaps in possibili-
ties for identifying disease; genetic analysis, as 
just one example, allows rapid identiﬁ cation of 
pathogens or pathogenic strains. At the same 
time, inequalities within societies and within the 
global community have become more marked. 
There are growing gulfs in the capacity of dif-
ferent nations and locales to take advantage 
of technological change. Civil conﬂ icts in dif-
ferent countries inevitably trigger health crises 
that draw the attention of both United Nations 
agencies and humanitarian organizations. Cri-
sis situations, in turn, deepen inequalities and 
create additional barriers to surveillance and 
intervention in conﬂ ict zones (3). 
This remarkable epidemiological, social, eco-
nomic, political and technological global 
landscape makes it imperative to ﬁ ll the gap 
in international guidelines and to address the 
ethics of public health surveillance explicitly. 
That is the aim of these international guide-
lines on the ethics of public health  surveillance. 
They were prepared by an international group 
of experts in surveillance, epidemiological 
research, bioethics, public health ethics and 
human rights. The authors of these guidelines 
represent leading research institutions and 
also nongovernmental organizations (NGOs) 
either involved in surveillance or representing 
groups and populations with a vital interest in 
both the beneﬁ ts and burdens of surveillance. 
The authors also represent countries in both 
the south and north, with different political 
systems, social values and priorities. 
The guidelines were prepared in collaboration 
with the global network of WHO Collaborating 
Dog and pig vendor at market day, Atsabe, Ermera.
Source: WHO / SEARO /Joao Soares Gusmao
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Centres for Bioethics, which initiated the proj-
ect. They also drew on the technical support 
of the US Centers for Disease Control and 
Prevention to ensure that the guidelines took 
account of the actual procedures for and cost 
of data collection, analysis and dissemina-
tion and can thus reasonably be used. The 
guidelines are based on a systematic literature 
review of relevant research and grey literature 
in accordance with the WHO Handbook for 
Guideline Development (5). 
The goal of the guideline development project 
was to identify key ethical considerations to 
guide resolution of controversies that may arise 
in surveillance, which itself is an ethical obli-
gation of governments. Speciﬁ c ethical issues 
are addressed in contexts that differ in terms 
of culture, values, resources, political traditions 
and institutional structures, with sometimes 
very different expectations for the impor-
tance of individual rights, community solidar-
ity and/or the good of society. The guidelines 
also address challenges that arise in contexts 
characterized by persistent injustice and/
or repeated violation of human rights. These 
guidelines cannot therefore provide concrete 
answers to all the difﬁ cult questions raised by 
public health surveillance. Rather, on the basis 
of a set of core considerations for the ethics of 
public health, the guidelines establish the duty 
to conduct surveillance, share data and engage 
communities transparently, while recognizing 
the limits of that mandate. The 17 guidelines 
should not be read in isolation from each other 
or from the discussion of each of them. They 
jointly lay out the issues that those involved in 
surveillance (including ofﬁ cials in government 
agencies, health workers involved in surveil-
lance, NGOs and the private sector) should 
consider and weigh carefully when making 
decisions about the collection, analysis, shar-
ing, communication and use of surveillance 
data. 
While the guidelines do not specify a mechanism 
for oversight, the conclusion is that, in view of 
the overarching imperative to conduct surveil-
lance, analyse the data and act on the results, 
responsibility and accountability must ultimately 
be based on a sustainable, practical mechanism 
for ensuring that the ethical challenges posed 
by public health surveillance are anticipated 
and addressed systematically and transparently. 
Countries should ensure implementation of 
these guidelines and monitor it regularly.
P214263_WHO Guidelines on Ethical Issues.indd   13 20/06/17   2:42 PM
14 Background
II. Background
Deﬁ ning public health surveillance
Some countries deﬁ ne surveillance narrowly, 
others quite broadly. These guidelines cover 
surveillance as broadly understood. In the 
 simplest formulations, surveillance is deﬁ ned 
as “continued watchfulness” (6) or “the mon-
itoring of events in humans, linked to action” 
(7). WHO generally deﬁ nes surveillance as “the 
continuous, systematic collection, analysis and 
interpretation of health-related data needed 
for the planning, implementation, and evalu-
ation of public health practice” (8). Health 
data are those pertaining to communicable 
and NCDs, injuries and conditions and their 
related risks and determinants. For infectious 
disease outbreaks (and events that suggest a 
“potential for international disease spread”), 
the International Health Regulations (2005) 
(IHR) deﬁ ne surveillance as “the systematic 
on-going collection, collation and analysis of 
data for public health purposes and the timely 
dissemination of public health information 
for assessment and public health response as 
 necessary” (9). 
Understanding of public health surveillance 
differs considerably from country to country. 
Although surveillance is usually described as 
systematic or continuous, not all countries, 
institutions or scholars single out the rou-
tine nature of public health surveillance but 
rather emphasize the purpose and function 
of data collection (see Table 1). Likewise, 
although disease and injury always ﬁ gure 
centrally, some deﬁ nitions include determi-
nants of important public health events (10) 
and environmental conditions that affect 
health (11). Vital registration of events like 
births and deaths, although often not specif-
ically described as part of a “public health” 
surveillance system, is often considered to 
be surveillance. 
Although international agencies often spon-
sor, subsidize and oversee national surveys 
in low- and middle-income countries to track 
trends in risk factors or health outcomes, 
national public health authorities are usu-
ally responsible for public health surveillance 
 systems and activities. The IHR, however, 
 recognizes surveillance data from beyond the 
formal channels of reporting, including unof-
ﬁ cial or informal sources, provided that they 
meet standards of reliability and validity. 
For some organizations and experts, only those 
activities in which the purpose of data gather-
ing has been deﬁ ned in advance and, indeed, 
in which the questions driving data collec-
tion are set in advance meet the deﬁ nition of 
public health surveillance (12). The  Australian 
 Department of Health uses a broader epi-
demiological deﬁ nition of surveillance: the 
 continuing scrutiny of all aspects of the occur-
rence and spread of disease that are pertinent 
to effective control (13). Some designations 
explicitly exclude case-ﬁ nding (and subsequent 
testing and treatment), public health investiga-
tions and epidemiological research (12), while 
others consider that “use of epidemiological 
Health worker collecting records and ﬁ lling out 
surveys with the inhabitants of Salto, Uruguay.
Source: WHO/TDR /Sebastian Oliel
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Bedside computer in the diabetic ward of the King’s Hospital, London, 1970s.
Source: WHO /Peter Larsen
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information” falls within the scope of surveil-
lance (14). A  surveillance system may thus 
cover not only infectious diseases and involve 
not only continuous data collection but may 
also include focused epidemiological studies; 
inspection of hazardous conditions or broad 
oversight of the potential danger posed by 
food, water or the environment; and screen-
ing at workplaces or in health establishments. 
Table 1 gives an overview of the activities that 
fall within public health surveillance.
While there may be broader and narrower 
deﬁ nitions, the understanding of surveillance 
is that data are collected with the intent of 
enabling public health action, whether direct 
intervention, priority-setting, resource alloca-
tion or advocacy. “Knowing about the health 
of a community,” noted one group of surveil-
lance specialists, “is the ﬁ rst step to making 
improvements that support healthy behaviours, 
identify and address unusual health events, 
and prevent and treat disease and injury.” (12) 
In addition to linking surveillance to action to 
achieve some goal, almost all countries, institu-
tions and experts underscore the importance 
of communicating surveillance results to those 
“who need to know”, including the public, 
policy-makers, national and international sci-
entiﬁ c communities, programme planners, 
public health authorities, medical institutions 
and funding agencies, to enable intervention, 
sustainable development or advocacy.
The landscape of public health practice is also 
changing rapidly with regard to the kind of 
data to which public health agencies have 
routine access. In some settings, data are 
recorded by hand and stored on paper; in oth-
ers, they are collected, stored and shared via 
sophisticated electronic systems. The era of 
“big data,” as discussed in section V, may hold 
enormous potential for the future of public 
health surveillance, broadly understood, and 
has already raised vexing ethical questions. 
In  some jurisdictions, surveillance systems 
could soon be linked directly to electronic 
health records. Interoperability between pub-
lic health surveillance data sources and clini-
cal practice is within reach, in both the public 
and the private health care sectors (15). Public 
health data can be used to inform automatic 
decision-support systems or computational 
tools to trigger alerts and warnings. Research 
has shown, further, that geospatial mobile 
phone data could accurately describe and pre-
dict the movement of individuals and thereby 
the spread of diseases like malaria and H1N1 
inﬂ uenza (16-18). 
These guidelines deﬁ ne public health surveil-
lance systems broadly, building on the general 
WHO deﬁ nition of continuous, systematic col-
lection, analysis, interpretation, and sharing of 
health–related data for advocacy and for plan-
ning, implementing, and evaluating public 
health practices. Even if systems are operative, 
however, new, focused studies are required to 
respond to epidemiological threats. Further, 
public health surveillance systems not only rely 
on but may also inform and improve clinical 
practice.
Surveillance: ethics, law and history
Nation states have established surveillance sys-
tems that differ in scope and purpose. Interna-
tional law and regulation have been important 
means of ensuring at least a basic level of 
public health surveillance in all countries. In 
1969, the WHO Member States adopted the 
IHR, a revision and consolidation of the Inter-
national Sanitary Regulations, as the frame-
work for strengthening health security in an 
increasingly interconnected world. They came 
into force in 1971 (19). The IHR impose a legal 
obligation on all Member States to have cer-
tain core public health capacities, including 
surveillance and data collection, with the goal 
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of preventing, controlling or responding to the 
international spread of disease. 
Experience with the SARS crisis of 2003 led the 
World Health Assembly to adopt a signiﬁ cant 
revision of the IHR on 23 May 2005 (9). While 
the IHR had originally focused on a short, ﬁ xed 
list of communicable diseases, the revised reg-
ulations – IHR (2005) – allow ﬂ exibility to target 
any disease that may constitute a public health 
emergency of international concern. They also 
establish an obligation to create core capacity 
for surveillance and outbreak response to dis-
ease and “public health events”. As of Novem-
ber 2014, however, 48 countries had failed 
to communicate their capacity or plans, and 
another 81 had asked for extensions to com-
ing into compliance (20). The recent outbreak 
of Ebola virus disease revealed that many 
countries had not satisﬁ ed their obligations 
under the IHR; only 64 countries – one third 
of those bound by the IHR – “had achieved 
these core capacities”. Nevertheless, while all 
countries are required to comply with the IHR, 
limited resources and political instability can 
pose obstacles to surveillance, and it may not 
be possible to overcome these obstacles with-
out international assistance. 
The IHR (2005) are limited in the sense that 
they provide mainly a framework for gover-
nance in addressing “public health emergen-
cies of international concern”. The framework 
is neither for constructing comprehensive 
surveillance systems nor for grappling with 
the ethical issues posed by surveillance sys-
tems and practices. International regulation, 
like national law and regulation, is an impor-
tant tool that establishes a duty to conduct 
surveillance while also setting limits on that 
practice. What is legal, however, is not always 
ethical. Ethics is an essential tool for critically 
evaluating law, regulation and practice and 
for addressing the value conﬂ icts that may be 
posed by surveillance. 
Local and national surveillance systems 
emerged in the nineteenth century, and almost 
all comprised physicians’ case reports. The 
data were initially used almost exclusively to 
document either social progress or misery (21). 
At the heart of the most bitter battles over 
individual rights and population health, how-
ever, were surveillance measures that made 
intervention at the level of individuals possible, 
with the discovery of germs and the realization 
that many diseases were spread from person 
to person. Interventions based on communica-
ble disease reports were sometimes welcomed 
(leading to referral to clinics, provision of food 
and clothing) but were sometimes a cause of 
alarm (when leading to mandatory vaccination 
or treatment, quarantine or deportation). Ofﬁ -
cial morbidity reports were usually protected 
against public disclosure by law, regulation, 
and practice. Surveillance was also the basis 
for population health measures, such as the 
pasteurization of milk, regulation of food and 
drug manufacture, housing reform and other 
measures that addressed the structural causes 
of disease. Resistance to such measures, 
largely on the part of independent and incor-
porated businesses, was often framed as an 
issue of individual rights.
Physicians, worried about interference with 
their patients and use of their time, often 
resented, resisted or simply ignored man-
dates for reporting. But not all monitoring 
of morbidity and mortality required iden-
tiﬁ cation of cases by name. Reporting of 
sexually transmitted diseases, for example, 
was often done by code instead of name in 
industrialized countries (21). Contact tracing, 
of course, required names, but most physi-
cians kept the index case anonymous when 
patients cooperated by providing the names 
of sex partners and adhering to treatment. 
Whether names were necessary or whether 
informed consent was required often framed 
debates as surveillance was extended, over 
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the course of the  twentieth century, to NCDs 
such as cancer, diabetes and stroke and to 
occupational exposures, substance use, road 
accidents, injuries, vaccination status and 
vaccine reactions (22).
During the twentieth century, it was often 
people affected by a disease or condition who 
challenged the need for surveillance; but, just 
as often, the story of surveillance has been 
one in which affected groups have demanded 
the “right to be counted” (22). NCD surveil-
lance, in contrast to infectious disease surveil-
lance, has been underfunded and “woefully 
inadequate,” even in high-income countries 
(23). Workers exposed to toxic hazards and 
citizens vulnerable to environmental pollut-
ants have sometimes joined social movements 
as a means of gaining both attention and the 
resources necessary for surveillance; however, 
the more common story is that chronic disease 
threats, particularly those of vulnerable popu-
lations, remain invisible. 
Global crises often expose systemic challenges 
that are insufﬁ ciently addressed. Undocu-
mented migrants with tuberculosis are still 
not included in statistics submitted to WHO 
by some countries (24, 25), but it would be a 
 mistake to assume that the only challenges are 
the absence of surveillance or under-reporting. 
Tuberculosis surveillance data, for instance, 
were critical for determining levels of funding 
from the Global Fund to Fight AIDS, Tubercu-
losis and Malaria. Surveillance staff sometimes 
found themselves under high pressure to reach 
what some criticized as unrealistic targets. 
They had to choose between showing “good” 
results or losing their jobs, adversely affecting 
the quality of data in some settings (26, 27).
These guidelines are based on the understand-
ing that surveillance is so fundamental a public 
health practice that its advancement cannot 
depend on crises or citizen protests to make 
the case for tracking disease for the sake of 
public health. While these guidelines represent 
a call to action, it is not a call to unrestrained 
action. Rather, public health surveillance, con-
ducted in a manner that anticipates ethical 
challenges and proactively seeks to reduce 
unnecessary risks, provides the architecture for 
social well-being. 
Industrial pollution. Moscow, Russia.
Source: WHO /Sergey Volkov
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III.  Framing the ethics of 
surveillance
Existing guidelines 
Limited academic literature on the practice of 
public health surveillance addresses the major 
ethical questions that arise in data collection; 
when the data are actually stored, used and 
shared; and data dissemination. The academic 
literature is (28), however, no substitute for 
guidelines that go beyond current disease-
speciﬁ c, national recommendations (29). 
In the decades since the Second World War, 
both international and national bodies have 
proposed ethical principles, guidelines and 
laws to govern research with human sub-
jects. In response to egregious harm inﬂ icted 
on individuals coerced into clinical research, 
new codes of ethics uniformly prioritized indi-
vidual self-determination and emphasized the 
importance of informed consent for research, 
while acknowledging that it would hardly be 
straightforward in complex situations to bal-
ance the protection of human research sub-
jects against the social beneﬁ t of the research. 
In the practice of clinical ethics, autonomy 
assumed a place of singular importance, rep-
resenting a fundamental change in a moral 
world view (30-33).
In its “International guidelines for ethical review 
of epidemiological studies” in 1991, CIOMS 
acknowledged that existing guidance focused 
on “patients and individual subjects” was not 
sufﬁ cient for studies involving “groups” of 
people. After considerable controversy, a con-
sensus emerged: CIOMS stressed the impor-
tance of the principles of research ethics ﬁ rst 
set out in the Nuremberg Code but recognized 
that application in the epidemiological  context 
would require  ﬂ exibility (34). The tradition 
that developed was one in which research 
ethics committees could waive a requirement 
for informed consent when the risk posed by 
epidemiological research was “no more than 
minimal” and obtaining consent would make 
the research “impracticable” (34).
While public health surveillance may share 
methodological strategies with epidemiologi-
cal research, it is not simply another form of 
research. In   surveillance a  community is the 
subject of concern. That surveillance is one of 
the responsibilities of  public health was rec-
ognized in 1991 by CIOMS, which described 
surveillance in emergency outbreak situations 
as clearly requiring exemption from ethi-
cal review and oversight. In dire situations, 
surveillance could not “await the formal 
approval of an ethical review committee” 
(34). Emergencies, however, accounted for 
only a small part of surveillance activities. 
Not until its 2009 revision did CIOMS guide-
lines explicitly support continuous case-based 
public health surveillance (in the absence 
of informed consent). The revision stated, 
“Several considerations support the com-
mon practice of requiring that all practitio-
ners submit relevant data [to public health 
surveillance registries]: the importance of 
having comprehensive information … about 
an entire population, the scientiﬁ c need to 
include all cases in order to avoid undetect-
able selection bias and the general ethical 
principle that burdens and beneﬁ ts should 
be distributed across the population.” (35) 
This position echoed that of the Nufﬁ eld 
Council on Bioethics in the United Kingdom. 
In 2007, the Council warned against allowing 
individuals to opt out of reporting, arguing, 
“We are aware of several examples [in which] 
consent requirements have or could have had 
serious negative consequences.” (36) Despite 
this sweeping endorsement of mandatory 
nominative case reporting without consent, 
the Council underscored the  inevitability of 
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making ethical judgements about the limits 
of surveillance (36).
Neither CIOMS nor the Nufﬁ eld Council pro-
vided more guidelines on ethics for public 
health surveillance, nor did they resolve the 
vexing problem of how to distinguish surveil-
lance from research on human subjects. Are 
there morally relevant differences between 
public health surveillance and research (4, 
37)? Do they require different general guide-
lines and oversight mechanisms? Does, 
indeed, public health surveillance require any 
kind of formal guidelines or continuous over-
sight? Drawing the line between research and 
surveillance – or between research and other 
forms of vital social inquiry such as quality 
improvement, implementation research, oral 
history or even journalism – has been chal-
lenging, but deﬁ nitional solutions have (to 
date) proved inadequate (38, 39). Accord-
ingly, a leading group of surveillance experts 
underscored the need “to move past the 
formal demarcation between research and 
practice” (29). These guidelines seek to do 
so, not by laying out new deﬁ nitions but by 
setting into bold relief both the centrality of 
public health surveillance to population well-
being and the need for appropriate ethical 
guidance and review – that is, for a para-
digm of accountability that responds to the 
demands of public health and that is distinct 
from the systems that have governed research 
for half a century.
Public health ethics
The discipline of public health ethics has 
developed rapidly during the past two 
decades. Its central focus has been on articu-
lating and exploring the ethical issues that 
arise in the pursuit of population health. This 
has resulted in a focus on concepts such as 
the common good, equity, solidarity, reci-
procity, and  population well-being. This is 
not to say that more individual values such 
as autonomy, privacy, and individual rights 
A crowd at a community event to launch a vaccination campaign.
Source: WHO /Garry Smyth
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and liberties are not also important ethical 
considerations; however, these more “social” 
or “public” values are reﬂ ected in related yet 
not wholly overlapping concepts that capture 
the broad importance of community and the 
afﬁ rmative duty to act. Some in the ﬁ eld use 
the language of solidarity (40), drawing on 
the communitarian tradition in public health 
(41); others describe the mutual obligations 
of reciprocity (42). The Nufﬁ eld Council on 
Bioethics sought to  capture the duties and 
 responsibilities of government in relation to 
public health by the concept of “steward-
ship” (36).
After a careful review, reﬂ ection and delibera-
tion, the WHO Guidelines Development Group 
determined that the following ethical consid-
erations are of particular importance for public 
health surveillance. They represent the back-
bone of the guidelines:
Common good: Surveillance is widely 
acknowledged to be a public good 
(43), and some of the beneﬁ ts it pro-
vides cannot be subdivided into indi-
vidual private beneﬁ ts because they are 
fundamentally shared (41, 44). Surveil-
lance is justiﬁ ed, fundamentally, as a 
requirement for the good of all. With-
out adequate oversight by public health 
bodies and the participation of individ-
uals and communities, the shared ben-
eﬁ ts of surveillance are at risk. There is 
a complex literature on economics and 
moral philosophy that seeks to deﬁ ne 
and distinguish the terms “public 
good”, “public goods,” and “the com-
mon good” (45). After careful delibera-
tion, the committee adopted the term 
“the common good” to capture the 
notion of public goods more broadly 
conceived than in the narrow economic 
sense.
Equity: Public health ethics is centrally 
concerned with the idea of equity. It is 
well established that social inequality 
has adverse effects on health (46). Not 
all inequality is within human control 
or is morally relevant. Morally prob-
lematic inequality is commonly referred 
to as inequity. A just or fair society will 
attempt to provide equitable conditions 
for humans to ﬂ ourish, with health as 
a central component. Equity some-
times requires that the most vulnerable 
people receive what may appear to be 
disproportionate resources: that is, the 
unfair distribution of risks requires addi-
tional resources to balance the scales. 
Public health surveillance can further 
the pursuit of equity by identifying the 
particular problems of disadvantaged 
populations, including global communi-
ties, providing the evidence for focused 
health campaigns and identifying the 
basis of unfair differences in health.
Respect for persons: Public health eth-
ics is concerned with the rights, liberty, 
and other interests of individuals as well 
as overall population well-being. When-
ever possible, individuals should be 
involved in decisions that affect them. 
In some cases, individuals should be 
free to make their own choices; in other 
cases, when population-level interven-
tions may be necessary, individuals can 
be consulted and involved in decision-
making. But many individuals (such as 
young children) cannot make their own 
choices, and the State has an obligation 
to protect them and promote their long-
term health interests. Undertaking pub-
lic health surveillance is, itself, arguably 
an expression of respect for persons. 
This further requires ensuring that data 
about individuals and groups are pro-
tected and risks for harm are minimized 
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to the greatest possible extent. Finally, 
surveillance further engenders respect 
for persons by making protection or 
amelioration possible. 
Good governance: Although good gov-
ernance is not an ethical principle but 
rather a political aspiration, it is subject 
to a number of ethical considerations. To 
ensure that the ethical challenges posed 
by public health action are addressed 
systematically and fairly, governance 
mechanisms must be accountable and 
open to public scrutiny. Although pro-
tection of the common good must 
draw on the best available evidence, 
decisions will have to be made in the 
face of uncertainty. Accountability, 
transparency and community engage-
ment are means of justifying public 
policy structures that promote respect 
for persons, equity, and the common 
good. Transparency requires that poli-
cies and procedures for surveillance be 
communicated clearly and that affected 
individuals or communities be aware of 
any decisions concerning them. Trans-
parency also requires public reporting 
of the results of surveillance (in ano-
nymized or aggregated form). Without 
such knowledge, communities cannot 
be empowered to demand government 
action or to protect themselves in the 
absence of alternatives. 
These are not the only relevant ethical consid-
erations with regard to the nature of surveil-
lance programmes and practice but the ones 
considered central to making decisions in the 
speciﬁ c context of public health surveillance 
by those involved in development of these 
guidelines. 
While over the past few decades the global 
discourse on research ethics has come to 
an agreement on how best to frame issues, 
public health ethics has not reached such a 
juncture. Thus, even in documents explicitly 
grounded in public health ethics, differences 
in language and emphasis remain. This docu-
ment is one of three recent WHO-sponsored 
initiatives to develop ethical frameworks 
for disease control. Building on the original 
“Guidance on ethics of tuberculosis preven-
tion, care and control” in 2010 (47), the 
“Ethics guidance for the implementation of 
the End TB Strategy” (48) addresses the most 
critical challenges to  reducing the  number 
of deaths from tuberculosis by 95% by 
2030 and the number of new cases by 90% 
between 2015 and 2035. The “Guidance for 
managing ethical issues in infectious disease 
outbreaks” (49) in 2016, in response to the 
outbreak of Ebola virus disease in West Africa 
in 2014–2015, underscored the importance 
of providing ethics guidance beyond “a spe-
ciﬁ c pathogen in isolation” to “cross-cutting 
ethical issues that apply to infectious disease 
outbreaks generally”. 
The three projects obviously have important 
continuity. All, for example, emphasize equity, 
justice, and the common good (sometimes 
expressed as “stewardship” or “reciproc-
ity”). All stress the importance of respecting 
the dignity of persons (sometimes emphasiz-
ing autonomy or privacy). Accountability and 
the importance of good governance either 
explicitly or implicitly informs all three. They 
also have relevant differences that reﬂ ect the 
subject of each. The tuberculosis guidelines, 
for example, address the problem of drug-
resistant disease and thus emphasize the harm 
principle. The guidelines on infectious disease 
outbreaks, framed as they were by concern for 
groups in conditions of tremendous vulner-
ability and the ways in which outbreaks can 
become crises, further ampliﬁ ed by fear and 
distrust, places greater emphasis on human 
rights. Given the need to make decisions in 
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the face of uncertainty, they also stress utility, 
proportionality and efﬁ cacy.
The ethical considerations outlined above and 
repeated and ampliﬁ ed in the guidelines that 
follow are, in the estimation of this commit-
tee, central to justiﬁ cation of surveillance as 
a core activity, beyond outbreaks or infectious 
disease situations. They must be applied in 
situations that may vary in fundamental ways. 
The guidelines recognize that trade-offs of 
values are sometimes inevitable. The local tra-
ditions and priorities in countries may some-
times result in a different balance between 
competing values and priorities. It is important 
to stress, however, that not all trade-offs are 
morally acceptable. Local, national, or regional 
circumstances may be characterized by gross 
injustice or violations of human rights. In these 
contexts, rather than serving the common 
good, public health surveillance may be used 
as an instrument for violation of respect for 
persons, equity, and justice. In countries where 
sex work is a criminal offense, for example, 
HIV surveillance can be used for oppression. 
Likewise, an occupational disease surveil-
lance system that results in routine dismissal 
of workers affected by silicosis, black lung, or 
asbestosis would be unacceptable. Appeal to 
“trade-offs” under such circumstances could 
well be a pretext for further oppression and 
should be guarded against.
The State is a source of both intrusion and 
protection. Some disease burdens and forms 
of health oppression simply cannot be made 
visible without State-sponsored surveillance 
(50). On the one hand, surveillance makes 
public health interventions to address inequi-
ties possible. On the other hand, surveillance 
may be used to impose additional burdens 
on those who are already disadvantaged. The 
only assurance that surveillance will amount 
to neither privilege nor punishment is atten-
tion to the ethical considerations described 
above: both burdens and beneﬁ ts should be 
critically weighed and then fairly distributed in 
a transparent manner in which States are held 
accountable. 
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IV. Guidelines
As a consequence of the development of ethi-
cal norms for the conduct of research during 
the past few decades, research ethics com-
mittees have been established in almost all 
countries. As surveillance does not fall under 
the rubric of research, however, there has 
been no systematic framework for continuous 
ethical oversight or analysis of the challenges 
posed by surveillance activities. The following 
guidelines are premised on the conclusion that 
ethical scrutiny of public health surveillance is 
necessary. 
The guidelines are, necessarily, not prescrip-
tive; rather, they seek to highlight trade-offs 
that must be carefully and routinely weighed. 
They do not provide concrete deﬁ nitions, 
measures, precise surveillance parameters 
or oversight mechanisms that might, on the 
surface, appear to make decision-making less 
complex. Concepts like “legitimate public 
health purpose”, “disproportionate burden”, 
“community engagement” and “good gov-
ernance” cannot be regarded as universal 
yardsticks for use by decision-makers. Rather, 
agreement on deﬁ nitions for use in different 
contexts lies at the very heart of the vexing 
political and ethical judgements that must be 
made: grappling with the meaning of con-
cepts in speciﬁ c local and national settings 
represents a ﬁ rst step in ethical engagement. 
The following  guidelines, then, cover (i) the 
broad responsibility to undertake surveillance 
and subject it to ethical scrutiny; (ii) the obli-
gation to ensure appropriate protection and 
rights; and (iii) considerations in making deci-
sions about how to communicate and share 
surveillance data. These guidelines represent 
a starting point for the searching, sustained 
discussions that public health surveillance 
demands. Like other international guidelines 
on research ethics, the ethics of surveillance 
will require continuous review and revision in 
the light of experience. 
Kim Pai factory, Bangkok, June 2015.
Source: WHO /Diego Rodriguez
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Guideline 1. Countries have an obligation 
to develop appropriate, feasible, sustainable 
public health surveillance systems. 
Surveillance systems should have a clear 
purpose and a plan for data collection, 
analysis, use and dissemination based on 
relevant public health priorities.
Member States have an ethical duty to pro-
tect population health – not only that of their 
citizens but that of all people within their 
borders, including refugees, undocumented 
workers, and individuals in transit (51) – and 
to address the disparities that characterize 
the distribution of morbidity and mortality. 
The duty to protect population health is the 
foundation of an afﬁ rmative responsibility to 
conduct public health surveillance. The exer-
cise of that responsibility may be assigned to 
subnational governmental bodies. 
Without public health surveillance systems, 
population health cannot be protected and 
inequalities cannot be adequately addressed. 
Inattention to pressing public health needs 
leads to erosion of trust. Thus, from the per-
spective of the common good, the failure of 
countries and the international community 
to undertake adequate public health surveil-
lance represents a central moral concern. The 
importance of population health thus imposes 
upon States an obligation to develop systems 
that capture data critical to identifying and 
responding to (outbreaks of) infectious dis-
eases, epidemic threats and the toll exacted 
by injuries and chronic disease, which demand 
environmental and occupational monitoring 
or investigation. A commitment to equity and 
justice can uncover the ways in which pat-
terns of morbidity and mortality reﬂ ect and 
contribute to social inequality. As such com-
prehensive systems are beyond the capacity of 
some countries, the international community, 
as described in Guideline 6, has the obligation 
to provide support. 
Passive systems of surveillance are often suf-
ﬁ cient, such as monitoring seasonal outbreaks 
of inﬂ uenza from incidence and prevalence 
rates that include neither names nor case veri-
ﬁ cation with costly laboratory tests for all indi-
viduals with inﬂ uenza-like syndromes. Even in 
the instance of inﬂ uenza, however, systematic 
community-based surveillance provides a more 
accurate depiction of outbreaks. The State 
might have to establish active surveillance sys-
tems, taking proactive steps, for example, to 
ﬁ nd data: this might require examining clinical 
records to ensure complete reporting and to 
conﬁ rm an inﬂ uenza diagnosis. Cancer reg-
istries in some countries have included such 
active surveillance. 
Surveillance systems often entail the enact-
ment of regulations and statutes that impose 
upon clinicians, health care administrators or 
laboratories a duty to report to public health 
registries. To ensure effective surveillance of 
disease priorities, it is often necessary to man-
date the reporting of individually identiﬁ able 
data, including names and other socio-demo-
graphic characteristics. Such intrusion on clini-
cal conﬁ dentiality is justiﬁ ed when names are 
required to ensure the collection of accurate 
data, which is separate from the need to target 
interventions. But accurate data and targeted 
interventions both rest on the moral obligation 
to prevent harm to others and the common 
good or to provide the best resources to pop-
ulations according to the burden of disease, 
as in the case of cancer registries. Guidelines 
11 and 12 outline the ethical limits to name-
based reporting. 
Public health surveillance activities require 
investment of societal resources to preserve, 
protect and promote health. In all countries, 
but especially in low-resource settings, allo-
cating societal resources for public health sur-
veillance requires prioritization. This issue is 
discussed further in Guideline 5. 
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Once surveillance data are available, Member 
States have the moral duty to use the data 
actively to promote better health outcomes. 
Even when resources limit the capacity of 
countries to take immediate action on the 
basis of the ﬁ ndings of public health surveil-
lance, the data provide the evidentiary basis 
for advocacy directed at both the national 
and global communities, thus potentially 
empowering the most vulnerable. The pur-
suit of equity establishes a warrant for sur-
veillance, and the global community should 
provide the necessary help in moving from 
collecting and analysing data to action (see 
Guideline 6).
Interior view: a nurse is examining two young children in the dining area of the home; the mother is standing 
to the left; further to the left is a large stove situated next to a ﬁ replace.
Source: The National Library of Medicine
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Guideline 2. Countries have an obligation 
to develop appropriate, effective 
mechanisms to ensure ethical surveillance.
Public health surveillance has inherent beneﬁ ts 
for the functioning of the public health sys-
tem, as well as risks. Countries should have an 
appropriate, effective mechanism for ensur-
ing adherence to ethical standards in both 
emergency and non-emergency situations. 
Decisions about changing an established sur-
veillance system can pose important ethical 
challenges. Examples of changes that may 
require ethical scrutiny include: collecting data 
elements that reveal stigmatized behaviour; 
adding new elements of data collection, such 
as measurements of CD4 counts as part of 
routine HIV/AIDS surveillance; adopting new 
uses for existing surveillance data, such as for 
case management or contact tracing; or using 
public health surveillance data for commercial 
or security purposes. 
In the case of research, review committees 
monitor adherence to ethics standards. Such 
an independent, impartial oversight mecha-
nism allows for close scrutiny and can ensure 
that relevant protection is in place. These 
guidelines do not recommend mechanisms 
that mirror those that have emerged in the 
context of research ethics. However, public 
health surveillance is currently not subject to 
routine oversight. It is the obligation of coun-
tries to decide the most appropriate processes 
for identifying and addressing the ethical 
issues that arise in public health surveillance. 
Box 1 provides some examples of existing 
mechanisms. Any mechanism or process 
should ensure ethical implementation of sur-
veillance without itself becoming an obstacle 
to achieving the larger public health goal. (We 
address the nexus of surveillance and research 
in Guideline 16.)
Such mechanisms of ethical oversight 
should effectively identify the risks and ben-
eﬁ ts of surveillance and suggest measures 
to enhance the beneﬁ ts, minimize the risks 
and ensure appropriate weighing of the com-
mon good, equity, and respect for persons. 
Oversight should be continuous, and any 
substantial changes proposed to the surveil-
lance system should be evaluated through an 
“ethical lens”. 
Ethical monitoring of surveillance can be facili-
tated and enhanced by training public health 
personnel. Such training can emphasize the 
importance of integrating ethical analysis early 
and explicitly when developing and imple-
menting a surveillance system. 
While the establishment of an indepen-
dent, impartial ethics oversight mechanism 
is warranted, concrete implementation will 
depend on the social, political, legal, and 
cultural context in which surveillance is con-
ducted (52). Research usually entails discrete 
projects with time-limited horizons, whereas 
surveillance usually involves continuous 
monitoring as opposed to a one-time review. 
The most appropriate mechanism for ethical 
scrutiny should be chosen in a transparent, 
accountable fashion. (See guidelines 2 and 
5 and the discussion of good governance in 
section III.)
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Box 1. Examples of oversight mechanisms
Public Health Ontario (Canada)
In 2012, Public Health Ontario published “A framework for the conduct of public health initiatives”. It 
applies an integrated approach for ethics review, in which all evidence-generating initiatives undergo ethi-
cal scrutiny proportionate to the level of risk. Its Ethics Review Board plays a vital role in helping to ensure 
that research and other initiatives conducted by Public Health Ontario are carried out in a manner that 
is consistent with the second edition of the Federal “Tri-council policy statement on ethical conduct for 
research involving humans and other relevant regulations, policies and guidelines”. The Ethics Review Board 
addresses research, evaluation, surveillance, and quality improvement projects that involve human partici-
pants, their data, or their biological materials. Membership of the Board complies with the provisions of the 
Federal policy statement with regard to expert representation and composition, with members selected from 
Public Health Ontario and public health units and academic institutions in Ontario. They have expertise in 
various public health disciplines and in methodology, law, and ethics; the members also include community 
representatives. (Source: https://www.publichealthontario.ca/en/About/Pages/Ethics-Review-Board.aspx)
Centers for Disease Control and Prevention, Public Health Ethics Unit (USA)
The Centers for Disease Control and Prevention established the Public Health Ethics Unit in the ofﬁ ce of 
the Associate Director for Science, which collaborates with the Public Health Ethics Committee. It provides 
support throughout the institution; its aims are to “integrate the tools of ethical analysis into day-to-day 
operations”. It provides training, fosters and sustains a culture of ethical analysis, and provides guidance 
for and support in ethics consultations. (Source: https://www.cdc.gov/od/science/integrity/phethics/)
National Health Service clinical governance committee (United Kingdom)
The National Health Service in the United Kingdom distinguishes between research and non-research 
activities. Individuals involved in audits, programme evaluation, or public health surveillance are directed 
to seek advice from the clinical governance ofﬁ ce of their local National Health Service organiza-
tion. (Source: http://www.nhs24.com/aboutus/nhs24board/boardmeetingsandcommittees/committees/
clinicalgovernancecommitttee/)
Public Health Ethics Consultation Service, WHO
The Global Health Ethics Unit at WHO created a new mechanism in 2015 to help colleagues working in 
public health to address ethical issues. Like those of the Ethics Review Board of Public Health Ontario and 
the Public Health Unit at the Centers for Disease Control and Prevention, the mandate of the Public Health 
Ethics Consultation Service extends beyond surveillance. Programmes and initiatives are not required to be 
reviewed by this service: WHO staff solicit advice as needed in order to maximize ﬂ exibility and ensure that 
ethical consultation is not viewed as a bureaucratic hurdle. Its advice is informal and non-binding. The group 
is made up of WHO staff, who receive continuing training in public health ethics and seek advice from the 
global network of WHO Collaborating Centres for Bioethics. (Source: http://www.who.int/ethics/en/)
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Guideline 3. Surveillance data should be 
collected only for a legitimate public health 
purpose.
Governments and others involved in public 
health surveillance should collect only infor-
mation that is relevant for legitimate public 
health purposes, such as to protect, enable 
or enhance public well-being, reduce morbid-
ity and mortality, increase access to the health 
system and services and reduce health dispari-
ties and thereby inequities. All further discus-
sions of public health surveillance in these 
guidelines is based on the assumption that it is 
undertaken exclusively for a legitimate public 
health purpose. 
Literature on good governance usually con-
siders legitimate measures to be those that 
are publicly defensible, morally justiﬁ ed and/
or socially acceptable in pursuit of a common 
good. (53, 54) Any collection of personally 
identiﬁ able information that does not meet 
these conditions would be ethically problem-
atic. A legitimate public health purpose is 
required not only for the collection of data 
but also for the further use of data already in 
hand. 
Data collected for clinical purposes (for exam-
ple to diagnose infectious disease, to moni-
tor microbial resistance, to monitor NCDs like 
diabetes or to track behaviour associated 
with coronary heart disease or obesity) can be 
used for legitimate public health surveillance 
purposes, provided that such use meets the 
criteria bar set in guidelines 1, 3, 4 and 7–14 
of this document. Such repurposing requires 
adequate protection of data security and con-
ﬁ dentiality (Guideline 10).
Children`s Environmental Health in India.
Source: WHO /Diego Rodriguez
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Guideline 4. Countries have an obligation to 
ensure that the data collected are of sufﬁ cient 
quality, including being timely, reliable and 
valid, to achieve public health goals.
Data should meet the most exacting yet 
reasonable standards with regard to com-
pleteness, uniqueness, timeliness, validity, 
accuracy and consistency for the purpose and 
the resources available to fulﬁ l that purpose. 
Where relevant, this requirement extends to 
external quality assurance of laboratory data. 
The quality of data is a precondition of their 
ethical use. Determining the adequacy of 
data, however, depends, in part, on whether 
they are to be used to intervene at the level 
of the individual (e.g. contact tracing) or the 
population (e.g. estimating the incidence 
and prevalence of a disease or exposure). 
Their adequacy will also depend on whether 
a disease is infectious, noncommunicable or 
environmental, and whether the condition is 
chronic or acute. How data quality is assured 
from a technical perspective will depend on 
the priority, the context and the type of sur-
veillance. While some countries and institu-
tions explicitly stress the accuracy or reliability 
of data (55), others value rapid collection of 
useful data over complete accuracy.
Countries have obligations to ensure suf-
ﬁ cient numbers of trained staff to generate 
and  competently analyse surveillance data 
and promote quality. The quality of surveil-
lance data can be improved not only by formal 
technical evaluation but also by regular audit 
and benchmarking against national and inter-
national norms (56). Countries have an obli-
gation to educate people who contribute to 
surveillance about its goals and to explain why 
surveillance is conducted, what risks might 
arise, how those risks can be minimized and 
any appropriate legal and ethical obligations. 
Individual health care workers, professional 
bodies, and agencies (like hospitals and labo-
ratories), in turn, have a professional obliga-
tion to support and contribute to maintaining 
the integrity of surveillance activities and to 
ensure that data of the best possible quality 
are obtained. 
Counterintuitively, data quality may be com-
promised by widely used performance-based 
funding mechanisms. Too great an emphasis 
on achieving targets, linked to funding, can 
undermine the integrity of surveillance. For 
example, countries may be pressured to pro-
duce data to secure resources, and staff may 
have to choose between providing either the 
data desired by funders or the correct data 
and risk losing their jobs. Realistic target-set-
ting at international and national levels and 
broader international support for surveillance 
(Guideline 6) are possible solutions to coun-
teract the scramble for funding that produces 
unreliable data.
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Guideline 5. Planning for public health 
surveillance should be guided by 
transparent governmental priority-setting. 
Public health surveillance involves the invest-
ment of resources that could be allocated to 
meet other goals, such as clinical care or pre-
vention (57). Furthermore, within the resources 
available for public health surveillance, 
 priorities must be set. Given competing goods, 
the allocation of scarce resources must inevita-
bly engage questions of equity and efﬁ ciency. 
As no absolute standard can guide such deter-
minations, it is critical that decision-making 
be transparent, fair and open to revision (58). 
Governments are accountable for how priori-
ties are set. Transparency is important because 
it fosters trust and creates conditions for citi-
zens to advance the common good individually 
and collectively (59).
Transparency is essential with respect to: (i) the 
aims and duration of any public health surveil-
lance activity, (ii) the rationale for such activity 
relative to explicit health or health care system 
goals, (iii) the intended beneﬁ ts and potential 
burdens to citizens and other actors of public 
health surveillance, (iv) the scope and methods 
to be used in collecting data, (v) the intended 
uses of data and by whom, (vi) the mechanism 
by which use of data will be monitored, (vii) the 
mechanism by which subsequent use of data 
would be overseen at community level and (viii) 
the recourse that citizens or other actors may 
have if public health surveillance fails to meet 
legal and/or ethical standards. Surveillance 
data should be publicly reported (see Guideline 
13) to the extent that they will increase public 
trust, serve the aim of promoting and protect-
ing public health nationally and internation-
ally and will not unduly harm any identiﬁ able 
group or exacerbate inequity (54, 58).
Citizens should have access to mechanisms 
to express their concerns and priorities with 
regard to surveillance. For example, commu-
nities may express concern about a potential 
cluster of birth defects or cancers that necessi-
tates not only targeted epidemiological studies 
but also the creation of surveillance systems. 
Priorities should not be set solely by experts 
nor by those with access to health ofﬁ cials and 
 policy-makers, neglecting populations with 
less opportunity to voice their concerns. 
Pandemic containment exercise (simulation), conducted by the Ministry of Indonesia with the support of WHO 
Indonesia.
Source: WHO / SEARO /Nursila Dewi
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Guideline 6. The global community has 
an obligation to support countries that 
lack adequate resources to undertake 
surveillance.
Some countries may be unable to establish 
and maintain public health surveillance of suf-
ﬁ cient quality, even for high-priority targets 
that could greatly reduce health inequalities 
and improve population health, because of 
severe resource constraints. Equity provides 
the ethical foundations for claims to interna-
tional support. The global community – inter-
national health organizations, NGOs, major 
foundations, countries with a global leader-
ship role – has an ethical responsibility to work 
collaboratively with these countries to support 
public health surveillance and subsequent 
interventions. The aim of this requirement of 
global justice is to reduce health inequalities 
among countries and improve global health. 
For example, preventing and limiting the 
global spread of disease was a key rationale 
for the obligations under the IHR. Given that 
outbreaks and risk factors do not recognize 
borders, the global community also has an 
interest in having sustainable surveillance sys-
tems, even in countries that do not have the 
means to establish and maintain them (20). 
Likewise, effectively addressing NCDs and 
environmental threats requires international 
support for surveillance (60, 61). Agencies 
with a strong capacity for surveillance should 
regularly update technical guidelines for best 
practices. The international community should 
help to ensure that both technical and ethical 
training is widely available.
Surveillance may require support not only 
for technical capacity, however, but also for 
systematic, formal ethical evaluation and 
improvement, as demonstrated by global 
 support for training in research ethics. Thus, 
international organizations also have an 
obligation to facilitate and encourage coun-
tries to practise good governance by meeting 
their ethical and legal responsibilities. When 
countries fail to protect the fundamental 
rights or interests of individuals or populations 
in public health surveillance, international sup-
port should be contingent on their rectifying 
such violations and wrongdoings.
An obligation to support does not give the 
global community license to ignore the pri-
orities of countries that require support or 
resources. International humanitarian orga-
nizations have expressed deep concern that 
surveillance is too often driven by the secu-
rity needs of high-income countries, creating 
ambiguities about who the chief beneﬁ ciaries 
of surveillance are (3). When a country’s deci-
sions have been made in a participatory, trans-
parent manner, the global community has an 
obligation to meet local surveillance aspirations 
that exceed or even conﬂ ict with the priorities 
set by international donors (62). For example, 
malnutrition may be a priority for surveillance 
in a country with limited resources, whereas 
international donors may view that concern 
as of lower priority than an infectious disease 
outbreak. Genuine partnerships may require 
reform of global health governance, shifting 
the priority from securitization, politics, and 
trade to “universal health values” (63).
Too often, data are collected locally but ana-
lysed at State or country level, with minimal 
feedback. Both the international community 
and country ofﬁ cials should encourage the 
analysis and use of surveillance data collected 
at the local level by the local level. Local analy-
sis and use can enhance accountability and 
the capacity to improve population health. 
When local analysis is not possible, analyses 
performed at central or national level should 
be shared with the local level. 
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Guideline 7. The values and concerns of 
communities should be taken into account 
in planning, implementing and using data 
from surveillance.
Ofﬁ cials, agencies, and organizations respon-
sible for surveillance should try to engage the 
population beforehand about the goals, pro-
cesses, and potential impacts (both positive 
and negative) of surveillance activities as a 
means of demonstrating respect for persons. 
When this is not possible or is not done, those 
responsible for surveillance must bear in mind 
that their work is being done without consid-
eration of the concerns of the community; 
those responsible for surveillance necessarily 
become stewards not only of the common 
good but of community interests. Engage-
ment is particularly important when a surveil-
lance activity disproportionately burdens a 
speciﬁ c population (e.g. through stigmatiza-
tion). Engaging with communities, especially 
those that have been historically marginalized, 
and empowering them to participate actively 
is particularly important. Given that some 
public health surveillance activities require 
coordination at local, national and interna-
tional levels and involve multiple actors, active 
inclusion and participation of communities 
may be  useful in building or sustaining trust 
across levels and implementing activities more 
efﬁ ciently and effectively.
It is often difﬁ cult to deﬁ ne a community, 
because geographical area is not the only 
salient characteristic. Shared traditions and 
values and a common identity may be impor-
tant deﬁ ning factors. Health conditions may 
also help deﬁ ne a community. 
The appropriateness of engagement is another 
subject of debate. Some advocates incorpo-
rate community engagement in the design, 
implementation, monitoring and evaluation 
of surveillance. Community engagement in 
the dissemination of results is warranted, par-
ticularly when the ﬁ ndings may result in stig-
matization or discrimination. For others, a 
commitment to engagement may be more ﬂ ex-
ible. Taking account of community values and 
concerns requires, at a minimum, that legiti-
mate authorities undertake public health sur-
veillance in a transparent manner in accordance 
with the principles of good governance. Active 
engagement of the community may involve 
meetings with community leaders, focus group 
discussions and other forums that provide an 
opportunity for members to clearly express their 
values and concerns (see Guideline 5 and the 
discussion of good governance in section III).
Box 2. Community engagement
A particularly compelling, ﬂ exible method for engaging communities is democratic deliberation. This is a 
structured method for decision-making that brings together diverse stakeholders to construct solutions to 
complex policy questions. Participants engage in discussion and dialogue, communicate their perspectives 
respectfully, and provide justiﬁ cation for their views in a way that everyone involved can grasp. The goal is 
to make pressing decisions while considering empirical evidence, communities’ lived experience, and values. 
The US Bioethics Commission (64) has used the deliberative method as it has grappled with difﬁ cult issues 
fraught with tension and has made available a variety of training tools (65). While it is only one means of 
ensuring citizen involvement and is not appropriate for all situations, it has been a staple not only of local 
and national but also global decision-making. For example, in June 2016, (66) some 10 000 citizens in 76 
countries expressed concern about climate change and recommended legally binding measures, including 
“reporting of [each nation’s] adaptation and mitigation efforts” to keep global warming below 2 °C. (67)
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Guideline 8. Those responsible for 
surveillance should identify, evaluate, 
minimize and disclose risks for harm before 
surveillance is conducted. Monitoring for 
harm should be continuous, and, when any 
is identiﬁ ed, appropriate action should be 
taken to mitigate it.
Even when public health surveillance is clearly 
justiﬁ ed to promote the common good, Mem-
ber States and those responsible for conduct-
ing surveillance should remain alert to the 
possibility that harm can be caused to both 
individuals and communities (Table 2). 
This does not mean that surveillance should 
not be conducted. Rather, those conducting 
surveillance have an obligation to identify 
potential harm beforehand, to monitor for 
harm during and after surveillance and to put 
in place processes to mitigate harm. Without 
continuous monitoring, mitigation is impos-
sible. This is vital, not only because it is wrong 
to cause unnecessary harm, but also because 
harm – to both individuals and communi-
ties, such as loss of property value or tourism 
 dollars – may also damage public trust in the 
programme and in public health in general. 
(See guidelines 5, 12 and 13 and the discus-
sion of good governance in section III.)
In some instances, countries have provided 
compensation for the harm that might 
 inevitably accompany surveillance. In the con-
text of SARS, Chinese Taipei gave people who 
were quarantined the equivalent of US$ 147 
(68). Basic welfare beneﬁ ts or sick pay for 
those deprived of work as a result of surveil-
lance are other possibilities. The possibility of 
compensation should not, however, pose a 
barrier to surveillance (69). 
There are many different types of harm: eco-
nomic, legal, psychological, social (and reputa-
tional) and physical. All should be considered in 
relation to surveillance (70-72). For example, a 
migrant or a person in another disadvantaged 
group may be identiﬁ ed as being at higher risk 
for an infectious disease through surveillance, 
and this could lead to stigmatization of the 
group. Relevant information must be handled 
very carefully: reputations can quickly be dam-
aged, with devastating results across a spec-
trum that may include not-yet-documented 
types of harm (73). Various moral values and 
ethical principles should be weighed and bal-
anced against each other and a judgement 
made about fair distribution of burdens and 
beneﬁ ts in different surveillance initiatives or 
systems in a transparent way (see discussions 
of equity and good governance in section III).
When, despite all efforts to mitigate harm, 
surveillance entails a predictable risk for harm 
(stigmatization, discrimination, expulsion or 
violence), additional precautions should be 
Table 2. Types of harm potentially related to disclosure of public health surveillance data
Type of harm Result
Physical Public attacks, spouse/partner abuse, domestic violence, delayed or 
inadequate treatment
Legal Arrest, prosecution, death penalty, expulsion
Social Discrimination, community discrimination, isolation, inability to access 
care or exclusion from care, rejection from the community
Economic Loss of employment or revenue, loss of health care services, loss of 
insurance, increased insurance premiums, increased health care costs, 
limited career options, loss of life resources, forced relocation
Psychological/emotional Distress, trauma, stigma
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taken to protect the individuals or commu-
nities at risk. The risk for serious harm may, 
in rare circumstances, be so great that sur-
veillance might be difﬁ cult to justify morally. 
In most cases, however, mitigation strategies 
can ensure that risks for harm are dealt with 
adequately. Once harm or potential harm is 
identiﬁ ed, action must be taken to reduce the 
risk, or a plan must be in place for reducing, 
removing or compensating for any harm.
As not all harm can be eliminated, the ben-
eﬁ ts of surveillance should be proportional to 
the risk for harm. Protective measures should 
include the way in which health authori-
ties present information or action to the 
media and the broader public.  Sensationalist 
 representations of statistical facts can, for 
example, result in reputational damage and 
extend the period of economic recovery for 
those affected by a health issue, as in the 
case of countries or communities identiﬁ ed as 
a source of an infectious outbreak. Processes 
and measures should be in place to miti-
gate some of the ﬁ nancial and other harm-
ful consequences of surveillance in order to 
minimize any negative consequences for a 
community and to maintain trust. Addition-
ally, given their mission to mitigate harm, 
politically neutral international humanitar-
ian organizations must not be hindered in 
situations such as civil conﬂ ict zones, where 
international agencies are constrained when 
it comes to recognizing “opposition parties 
as operational partners” (3).
Notably, public health professionals them-
selves sometimes require protection. As 
champions of the common good, they must 
be free to report without fear of reprisal. As 
surveillance ofﬁ cials have a responsibility to 
speak up, they should have protection. This 
idea is established in the IHR, which protects 
the conﬁ dentiality of those who report a veri-
ﬁ able outbreak or a public health event out-
side ofﬁ cial channels. 
Health brigades in Chiapas, Mexico, during the 
epidemic of H1N1 inﬂ uenza, 2009.
Source: WHO /Harold Ruiz
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Guideline 9. Surveillance of individuals or 
groups who are particularly susceptible 
to disease, harm or injustice is critical 
and demands careful scrutiny to avoid 
the imposition of unnecessary additional 
burdens.
Individuals or groups in situations of height-
ened vulnerability bear an undue proportion 
of health problems. Responsible authorities 
should make special efforts to ensure that 
these populations are included in surveillance 
in ways that will empower them. How exactly 
situations of vulnerability should be deﬁ ned 
is a subject of dispute in the literature (74). 
Vulnerability may be diffuse, affecting large 
communities with limited economic develop-
ment, limited access to health care facilities, 
educational deprivation, occupational risks or 
wider disadvantages in society. Public health 
surveillance and health information systems 
can provide valuable information to aid the 
development of health programmes and ser-
vices to address their health problems and the 
underlying determinants of health, such as 
clean water, food security, or gender equality. 
To promote equity, surveillance should focus 
on the speciﬁ c problems of these vulnerable 
communities.
People with particular susceptibility to disease, 
harm or injustice are also at increased risk for 
further burdens, such as discrimination and 
stigma, attributable to surveillance activities 
or ﬁ ndings. For example, refugee groups and 
undocumented migrants with a higher disease 
burden may be seen, wrongly, as the cause of 
disease outbreaks. Similarly, workers with an 
occupational disease, such as silicosis, who 
lack access to adequate legal support may 
be dismissed from work rather than receiving 
treatment or compensation. Wherever pos-
sible, susceptible groups should be identiﬁ ed 
before surveillance activities begin in order to 
minimize the risk for harm. In surveillance pro-
grammes, there should be constant monitor-
ing for (further) harm to those in conditions of 
particular vulnerability. When harm does occur, 
a mitigation strategy should be put in place 
(see Guideline 8). 
The HIV oral test on a brothel bed in Belém do Pará, 
Brazil.
Source: Laura Murray
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Guideline 10. Governments and others who 
hold surveillance data must ensure that 
identiﬁ able data are appropriately secured. 
Responsible data collection and sharing prac-
tices should ensure the security of the data 
collected in order to respect persons and safe-
guard the privacy and other interests of the 
individuals and communities concerned (50). 
Every effort must be made to secure records 
to prevent unauthorized disclosure. Security 
is  different from privacy and conﬁ dential-
ity, yet it is an essential component of each. 
“Security” in this context consists of opera-
tional and technological safeguards to protect 
personal data from unauthorized access or 
disclosure. Maintaining information security is 
not fool-proof, as electronic databases can be 
inﬁ ltrated.
Governments and others who hold surveil-
lance data must take appropriate techni-
cal and organizational steps to protect data 
against accidental or unauthorized access, 
destruction, loss, use or disclosure, whether 
the data are collected and stored in paper 
or electronic (digital) format. All personnel 
with access to public health surveillance data 
should be trained annually in data security pro-
cedures and made aware of their professional 
ethical responsibility to protect the data and 
the public. The level of security must be appro-
priate to the risks and the nature of the data 
to be protected, taking into account the state 
of the art and the cost. In particular, sensitive 
information, which raises the risks of individu-
als and communities for stigmatization or dis-
crimination, should be subject to speciﬁ c and 
especially rigorous security safeguards. 
The imperative to secure data should not be 
considered a license to refuse to use or share 
surveillance information effectively for legiti-
mate public health purposes. (See guidelines 
14–17 on sharing and the discussion in Guide-
line 2 on meaningful ethics training.)
Staff at the Medical Records Ofﬁ ce sort through patient ﬁ les at Karapitayam Hospital, Galle.
Source: WHO / SEARO /Gary Hampton
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Guideline 11. Under certain circumstances, 
the collection of names or identiﬁ able data 
is justiﬁ ed.
In some instances, the collection of names 
or identiﬁ able data is both technically and 
ethically imperative. Effective surveillance may 
require the de-duplication of records (that is, 
avoidance of double-counting, which can lead 
to overestimates of incidence or prevalence). 
Names and other unique identiﬁ ers (social 
security numbers, identity card numbers) 
may also be essential for longitudinal surveil-
lance registers, which require correct linkage 
of records on the same individual and/or their 
relatives or contacts over time. Unique identi-
ﬁ ers may likewise be required to link data from 
different sources (for example, registries of 
tuberculosis and HIV, or birth defects and Zika 
virus infection). Critically, names and other 
speciﬁ c identiﬁ ers are required for outbreak 
investigation or case follow-up and contact 
tracing (e.g. to identify and offer testing and 
treatment to the sexual and needle-sharing 
partners of people with sexually transmitted 
infections).
There has been disagreement over whether 
unique identiﬁ ers can be used instead of 
names. Unique identiﬁ ers are expensive to cre-
ate and, if constructed in a fashion that allows 
accurate data linkage, could easily be linked 
back to names. Some countries experimented 
with coded reporting for HIV infection before 
ultimately adopting nominative systems. While 
such systems were initially the only politically 
viable solution, they were abandoned when 
they were found not to meet federal funding 
standards for reliability and validity. However, 
technological advances have created new 
possibilities. Digital data can be scrambled 
and encrypted into unique identiﬁ ers that are 
perhaps impossible to trace back to individu-
als. Good governance requires that the trade-
offs of using names as opposed to unique 
 identiﬁ ers or encryption be the subject of 
continuing, transparent, public discussion that 
takes into account surveillance system require-
ments, changing technical capacity, risks, and 
evolving norms with regard to unique identi-
ﬁ ers (which may become ubiquitous) and their 
legitimate use (75).
Another important consideration in the col-
lection of data is the geographical location of 
Names and addresses of people with dread diseases 
were regularly reported in newspapers until the 
1960s.
Source: New York Times, July 22, 1916. Public Domain.
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individuals, which can be an indirect identiﬁ er. 
It is ethically important to prioritize conﬁ denti-
ality during the collection of geolocation data 
and also for the release or sharing of global 
positioning system data, which should be 
 geo-masked to minimize risk of disclosure, pre-
serving spatial distribution but preventing iden-
tiﬁ cation of cluster-exact geo-coordinates (76).
When the collection of names or unique 
 identiﬁ ers is considered imperative, this 
requirement should be made explicit in plan-
ning the programme. Not only will countries 
make different judgements, but the require-
ment for names may not be uniform within 
countries. Personal data may be required only 
at local level, while anonymized or aggregate 
data may be sufﬁ cient at higher levels in a 
country or globally.
Drone in clear sky. Robert Lynch.
Source: CC0 Public Domain
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Guideline 12. Individuals have an obligation 
to contribute to surveillance when reliable, 
valid, complete data sets are required and 
relevant protection is in place. Under these 
circumstances, informed consent is not 
ethically required.
There is a long history of objection to public 
health surveillance without informed consent. 
Nevertheless, informed consent is not the 
default in public health surveillance. Many coun-
tries have enacted laws that require such sys-
tems to collect personal data without consent, 
subject to legislatively prescribed safeguards. 
All individuals in a population are likely to 
beneﬁ t from surveillance programmes. Indi-
viduals, therefore, have a reciprocal obliga-
tion to contribute to surveillance and thereby 
promote the common good. Even when the 
potential beneﬁ t to any one individual is 
small, as the epidemiologist Geoffrey Rose 
famously pointed out, the beneﬁ t to the 
community as a whole may be large (77). 
Population beneﬁ ts provide the moral obliga-
tion for individuals to contribute. If it is pos-
sible to opt out (and too many people do so), 
public health might be unacceptably com-
promised (78). Seeking informed consent is 
often not feasible in practice, e.g. from large 
populations. It may be prohibitively costly 
and unwarranted when the risks are low (as 
in some epidemiological research in which 
CIOMS has allowed waiving of consent). In 
some cases, however, consent is the norm, 
such as in routine descriptive health sur-
veys. It is the obligation of the public health 
authorities accountable for surveillance to 
assess the importance and feasibility of seek-
ing informed consent. It is important to clar-
ify that, when consent is required, it must be 
genuinely voluntary. 
Whether or not consent is sought, informa-
tion about the nature and purpose of surveil-
lance and about any risk for harm should be 
publicly accessible (see Guideline 13). Rel-
evant protection and adequate governance 
mechanisms (Guideline 2 and the discussion 
on good governance in section III), appropri-
ate ethics training (guidelines 2 and 6) and 
data security (Guideline 10) will enhance 
trust in surveillance systems and ensure 
 protection. 
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Guideline 13. Results of surveillance must 
be effectively communicated to relevant 
target audiences. 
There is compelling, widely accepted moral 
justiﬁ cation for dissemination of the results 
of surveillance to relevant target audiences, 
although it is not a substitute for ameliora-
tive action on the part of those responsible for 
surveillance. At the local level, relevant target 
audiences include the community, community 
ofﬁ cials and opinion leaders, health care pro-
viders (doctors, nurses, health care workers), 
policy-makers, health advocates and health 
volunteers. The relevant target audiences may 
also include Member States, national and 
international agencies, and NGOs.
Although CIOMS guidelines are focused 
on research, they stress the importance of 
communicating results, both positive and 
negative, to “promote and enhance pub-
lic discussion”. Without dissemination, the 
social value of the work cannot be realized. 
In the absence of appropriate dissemination, 
those who collect data, including surveillance 
data, might rightly be accused of exploiting 
the individuals and groups whose health data 
they collect and analyse in the name of the 
common good. The Nufﬁ eld Council on Bio-
ethics argued that, for dissemination to be 
considered appropriate, those from whom 
data are collected should understand the 
implications of the results for both health care 
and prevention (35).
Surveillance ﬁ ndings should be communicated 
concisely in a way that is understandable to 
a lay audience and sensitive to community 
concerns (see Guideline 7). Communica-
tion should not seed panic but alert people 
to relevant risks in a sensible manner. Mass 
mailings, toll-free information hotlines, social 
media, newspapers, seminars, and public 
meetings are all possible means for conveying 
surveillance information to the communities 
from which data were collected and analysed 
and to the public. In resource-limited set-
tings, street theatre, and folk art and other 
community-based methods can be adopted 
for the same purpose. Communication should 
also provide meaningful information for phy-
sicians, hospital managers and other relevant 
target audiences.
The communication of knowledge is a double-
edged sword: on the one hand, knowledge 
may clearly empower; on the other, it may 
lead to injury, stigmatization or discrimination. 
A decision not to broadly publish data might 
be justiﬁ ed in exceptional circumstances, 
when doing so might cause signiﬁ cant harm. 
Likewise, if the affected population is so small 
(for example, cases of very rare cancers) that 
identiﬁ cation of individuals, however inadver-
tent, might be inevitable, communication can 
be limited to preserve privacy (79).
Decision-makers must also weigh the harm 
that could result if affected communities are 
not informed and thus deprived of knowl-
edge and the ability to take action to reduce 
the risks and the capacity to engage in advo-
cacy (see Guideline 13). Those responsible for 
public health have an afﬁ rmative duty to miti-
gate the burdens that communication might 
impose on individuals or groups that are more 
susceptible to harm or injustice.
There is continuing debate about when, if 
ever, those responsible for the design and 
conduct of surveillance are ethically obliged 
to inform the subjects of surveillance about 
individual results or diagnosis and then 
refer them to the appropriate service (80). 
For example, in the early days of the HIV 
epidemic, when treatment was not avail-
able, blinded seroprevalence studies were 
considered ethically acceptable. In these 
population-based surveys, HIV status was 
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not communicated to the study participants. 
With advances in HIV diagnosis and manage-
ment, however, the ethical consensus shifted 
(81). Guidelines now recommend that sur-
veillance systems report results back to con-
senting individuals (80, 82, 83). Guidelines 
also recommend that, after returning results 
to individuals, those with positive results be 
referred for proper clinical evaluation, treat-
ment and follow-up at nearby health facili-
ties. The guidelines also encourage partner 
testing (76) and referral for psychosocial 
support. This example underscores the 
importance of surveillance systems having 
an engaged oversight body to deal with such 
issues and make changes on the basis of new 
evidence or emerging best practices in other 
jurisdictions (Guideline 2).
Relevant ethical considerations in making a 
judgement about returning information to 
individuals include feasibility, the possibility of 
taking action and the potential beneﬁ t to the 
individual. 
Map of parasitic disease epidemic area in China at the National Institute of Parasitic Diseases in Shanghai, 
China. 16 May 2010.
Source: WHO / TDR /Simon Lim
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Guideline 14. With appropriate safeguards 
and justiﬁ cation, those responsible 
for public health surveillance have an 
obligation to share data with other national 
and international public health agencies.
For a public health surveillance system to be 
effective, equitable, and promote the com-
mon good, it must be capable of receiving and 
linking data from public agencies responsible 
for public health. For example, because of the 
stringent data security that has surrounded 
HIV surveillance, there have been situations in 
which data on HIV status have not been shared 
with those responsible for tuberculosis surveil-
lance, obviating systematic identiﬁ cation of 
cases with co-infection. Public health work-
ers cannot respond appropriately to swiftly 
changing infectious diseases in real time or 
take appropriate action in the case of chronic 
conditions without access to appropriate data. 
The same is true of occupational exposures. 
There have been examples in which agencies 
responsible for tracking occupational diseases 
have not shared data (despite the absence of 
a prohibition) with agencies responsible for 
worker protection and  workplace regulation 
(23). A review of the literature indicated that 
much of the failure to share information is due 
to poor planning rather than safety concerns. 
Programmes have experienced technical dif-
ﬁ culties in sharing data, some data requiring 
conversion (e.g. birth year to age) in order to 
link databases (84, 85). 
Public health systems should establish frame-
works to enable secure sharing of data (see 
Guideline 10) with other national and inter-
national agencies. Early collaboration to align 
processes in order to avoid foregoing beneﬁ ts 
or wasting resources is ethically warranted. 
Ethical frameworks for sharing should respect 
persons by ensuring that only the data required 
to fulﬁ l a sufﬁ ciently important, legitimate 
public health purpose are shared, that data are 
not shared more broadly than necessary, and 
that data are not subsequently re-shared by 
other agencies, except under the conditions 
speciﬁ ed elsewhere in this document, e.g.  in 
guidelines 16–17. When the protection of 
different datasets is not equivalent, the more 
stringent privacy standard should be applied. 
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Guideline 15. During a public health 
emergency, it is imperative that all parties 
involved in surveillance share data in a 
timely fashion. 
The collection and sharing of data are essen-
tial activities in ordinary public health practice. 
During emergencies, data-sharing takes on 
increased importance because of the urgency 
of the situation, uncertainty in the face of 
incomplete or changing information, the com-
promised response capacity of local health sys-
tems and the heightened role of cross-border 
collaboration. For these reasons, “rapid data 
sharing is critical during an unfolding health 
emergency” (86). It not only constitutes 
good public health practice but is ethically 
 imperative. Ethically appropriate, rapid shar-
ing of data can help in identifying etiological 
factors; predicting disease spread; evaluating 
existing and novel treatment, symptomatic 
care and preventive measures; and guiding 
the deployment of limited resources. As dis-
cussed in the WHO guidance on managing 
ethical issues in infectious disease outbreaks 
(49), clinical and research data that are crucial 
for emergency response should also be shared. 
Data-sharing is also an obligation under the 
IHR in both health emergencies and infectious 
disease outbreaks.
As part of continuous pre-epidemic prepared-
ness, countries should review their laws, poli-
cies and practices on data sharing to ensure 
that they adequately protect the conﬁ den-
tiality of personal information and address 
other relevant ethical questions, such as set-
tling disputes about the ownership or control 
of surveillance data. Efforts should be made 
to ensure that rapid sharing of surveillance 
information with immediate implications for 
protecting public health and advancing the 
common good should not preclude subse-
quent publication in a scientiﬁ c journal (87). 
Medical student and district surveillance ofﬁ cer investigating suspected Ebola cases in Western Region of 
Sierra Leone.
Source: WHO /Stéphane Saporito
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Guideline 16. With appropriate justiﬁ cation 
and safeguards, public health agencies may 
use or share surveillance data for research 
purposes.
Surveillance data have often served as a foun-
dation for important public health research 
(88-90). For example, cancer registries have 
been used in longitudinal epidemiological 
studies on survival and treatment efﬁ cacy. It 
may be permissible to share surveillance data 
with researchers undertaking studies that (i) 
are sufﬁ ciently important for advancement 
of the common good and (ii) would not be 
feasible without access to the surveillance 
data in question. There may sometimes be 
disagreement about what should be con-
sidered  “sufﬁ ciently important” research 
to justify sharing of surveillance data for 
research purposes. This is a matter that local 
governments, public health authorities and/
or research ethics committees (as described 
below) should judge, taking into account the 
considerations and guidelines set out in this 
document. 
Sharing of surveillance data for research pur-
poses requires appropriate safeguards, such as 
ethical oversight (see Guideline 2), anonymiza-
tion, and data security. While the kind of ethi-
cal review required for conducting research is 
not appropriate for conducting public health 
surveillance, surveillance data should be shared 
only for research projects that have been 
reviewed and approved by an appropriate 
research ethics committee or another appro-
priate body, consistent with international 
and local standards on the ethical conduct of 
research. In making decisions about granting 
access to surveillance data, ethics committees 
should consider the potential public health 
impact of research (Is the research sufﬁ ciently 
important, or does it have, in the language of 
CIOMS, “social value”?), the risks to the sub-
jects involved, the measures in place to protect 
privacy, and the importance and feasibility of 
seeking consent. 
Striking the appropriate balance between 
safeguards and research advancement will 
sometimes be challenging. One controversial 
way of sharing sensitive information on drug 
use has been to delete any information on 
substance use disorders from individual clinical 
records released to researchers. Such protec-
tion in the name of privacy has become the 
centre of controversy in the context of a wide-
reaching opioid epidemic. One group of critics 
has argued that this has left researchers “ﬂ y-
ing blind” (91).
Researchers who have been provided with 
surveillance data should inform public health 
authorities about their ﬁ ndings. Before surveil-
lance data are shared with researchers, there 
should be agreement about: appropriate data 
uses, restrictions on data re-sharing, adequate 
acknowledgement of the data source in publi-
cations, and data destruction conditions at the 
end of the research phase. 
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Guideline 17. Personally identiﬁ able 
surveillance data should not be shared 
with agencies that are likely to use them to 
take action against individuals or for uses 
unrelated to public health. 
While aggregate public health data may 
be widely shared with agencies outside the 
health sector and non-state actors responsible 
for public welfare, sharing personally identi-
ﬁ able data is a fundamentally different mat-
ter. Access to such personal information by 
agencies responsible for national security, law 
enforcement, or the allocation of social ben-
eﬁ ts should usually be allowed only after legal 
due process. To preserve trust in public health 
surveillance systems, there should be compel-
ling justiﬁ cation for sharing identiﬁ able data 
for non-public health uses.
Inappropriate sharing of surveillance data is 
especially controversial in countries in which 
law enforcement or other agencies have been 
implicated in systematic violations of human 
rights. In these contexts, collaboration with 
law enforcement agencies may undermine 
trust in public health surveillance, creating a 
disincentive for seeking care or honest report-
ing of data. This is a particular concern for 
individuals or groups in situations of particular 
vulnerability (92). Further, such unwarranted 
sharing will potentially inﬂ ict long-term dam-
age on public health efforts more broadly. 
The governance mechanisms recommended in 
Guideline 2 should ensure that the  exceptional 
conditions, if any, under which identiﬁ able sur-
veillance data may be shared are speciﬁ ed and 
made transparent. Such a review will require 
determination of whether the threat is of suf-
ﬁ cient magnitude to warrant potential damage 
to the integrity of and trust in public health sur-
veillance systems. Sanctions must be in place 
to prevent inappropriate data-sharing by public 
health agencies and inappropriate use of data 
by agencies outside the public health sector.
WHO Immunization ofﬁ cers visit Quang Binh Province, Viet Nam to monitor the Measles-Rubella Immunization 
campaign.
Source: WHO / WPRO /Emmanuel Eraly
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A barcode is placed at the entrance of houses. After being ﬂ ashed with a smartphone, the barcode provides 
information about whether the house was controlled and declared dengue free or not.
Source: WHO/TDR /Catalina Cardenas
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V.  The shifting boundaries of 
surveillance
Various “non-State” actors are involved in 
public health surveillance, including NGOs, 
faith-based organizations, professional 
 organizations, research institutions, funding 
agencies, and supranational agencies like 
WHO and the European Centre for Disease 
Prevention and Control. Public surveillance 
functions may even be outsourced to private 
companies. This may be a cause of concern, 
as the data may no longer be owned by and 
accessible to State agencies. Nevertheless, the 
vicissitudes of surveillance mean that any set 
of ethical guidelines must cross boundaries – 
not only national boundaries but lines that 
have traditionally separated the public from 
the private (93).
The problem of blurred boundaries has 
become even more complicated in the era of 
big data. By “big data”, we refer to both the 
increased volume of data that can now be col-
lected and stored, usually in digital form, and 
the computational power available to pro-
cess it rapidly. The ubiquitous use of personal 
computers, smartphones, wearable devices, 
closed-circuit cameras, genetic sequencers, 
semi-autonomous drones, and other technol-
ogies means that we produce a steady stream 
of digital data. 
A data-centric technological revolution has 
generated great enthusiasm about the emerg-
ing potential beneﬁ ts of mining electronic 
health records, genomic data and other biolog-
ical materials, social media communications, 
satellite imagery and other digital datasets to 
identify emerging disease threats, interrupt 
foodborne disease outbreaks and improve col-
laboration among public health organizations. 
Drones have been hailed as a “game changer” 
in disease surveillance. Some have argued that 
drones could uniquely pinpoint an outbreak 
by identifying a rapid population exodus from 
a disease zone (94-96). Others are scepti-
cal about “drone utopianism”, arguing that 
drone surveillance should not be a health pri-
ority for countries with limited resources (97).
Other new technologies, such as phylogenetic 
analysis of HIV, hold similar promise and peril, 
involving both use and failure to use data. Indi-
viduals who generate information through per-
sonal devices are probably unaware of the range 
of potential subsequent uses of their data. It is 
unclear whether the private sector has an obli-
gation to share those data with public health or 
government ofﬁ cials. Custodians of such data 
should be aware of the issues that could arise 
and be involved in discussions about legitimate 
data-sharing and the steps that should be taken 
to monitor risk and prevent harm. 
There have been mounting calls for addi-
tional research and ethical analysis on issues 
related to big data (98). The place of big 
data and digital disease detection in the 
public health surveillance landscape remains 
undetermined, and additional work should 
be done on privacy and anonymity, the inte-
gration of public and private data sets and 
issues of data validity and reliability (99). The 
Deputy Director for Surveillance and Epide-
miology at the Bill & Melinda Gates Foun-
dation recently sounded an important call: 
“We need ethicists to be working on some 
of these problems.”
In order to remain proactive rather than reac-
tive, addressing these issues must represent 
the next frontier. While these guidelines are a 
place to start in addressing issues at the inter-
section of surveillance and big data, the chal-
lenges of this swiftly changing environment 
should be subject to continuing analysis and 
ethical monitoring. This challenge must be 
taken up by the global community. 
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Sphere and continents with binary code zero – one.
Source: CC0 Public Domain
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• What is the ethical obligation to undertake public health surveillance? 
• What are the risks of conducting disease surveillance? How should such 
risks be balanced against population level beneﬁ ts? 
• When and how must relevant communities be engaged in the 
development of surveillance plans? 
• How should the conﬁ dentiality of surveillance data be protected? 
• What are the ethical obligations to share relevant public health 
surveillance data across public health authorities? With public health 
researchers? With communities and individuals who have contributed to 
surveillance systems? 
• Are there circumstances when data sharing must be strictly prohibited?  
• What institutional mechanisms should be established to ensure ethical 
issues are systematically addressed prior to data collection, use, and 
dissemination?
These are core questions that those involved in public health surveillance 
have grappled with for more than a century. To address these and 
other pressing concerns an international group of experts has developed 
the WHO Guidelines on Ethical Issues in Public Health Surveillance. Based 
on a set of core ethical and policy considerations, these 17 guidelines 
establish the afﬁ rmative duties to undertake surveillance, share data, and 
engage communities, while recognizing the limits of surveillance. They will 
be applied in situations characterized by fundamental cultural, economic, 
and political variability. The goal, therefore, is to enable critical discussion 
about legitimate ethical tensions and trade-offs and the appropriate 
governance and oversight of surveillance.
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